Global Blood Therapeutics, Inc.
GBT was delisted on the 4th of October, 2022.
1 hedge funds and large institutions have $68 invested in Global Blood Therapeutics, Inc. in 2023 Q1 according to their latest regulatory filings, with funds opening new positions, increasing their positions, 0 reducing their positions, and 1 closing their positions.
50% less funds holding
Funds holding: 2 → 1 (-1)
100% less capital invested
Capital invested by funds: $42.1K → $68 (-$42K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BTI
Blue Trust Inc
Alpharetta,
Georgia
|
-$42K |
GBT Hedge Fund Activity: Q1 2023 in Review
1 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Global Blood Therapeutics, Inc. (GBT) for Q1 2023, worth a combined $68 — down 100% from $42.1K a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of GBT and 0 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.
The largest seller was Blue Trust Inc, exiting entirely with an estimated $42K sold.
- 1 institutional investor held Global Blood Therapeutics, Inc. (GBT) as of Q1 2023, down from 2 in Q4 2022.
- Funds reported $68 of Global Blood Therapeutics, Inc. stock for Q1 2023, down 100% quarter-over-quarter.
- 0 funds opened new Global Blood Therapeutics, Inc. positions in Q1 2023 and 1 closed out, a net change of -1 holder.
- The largest Global Blood Therapeutics, Inc. seller in Q1 2023 was Blue Trust Inc, an estimated $42K sold.
Based on aggregated 13F filings for Q1 2023.